Lead-time bias does not falsify the efficacy of early salvage radiotherapy for recurrent prostate cancer

Lead-time bias does not falsify the efficacy of early salvage radiotherapy for recurrent prostate cancer: Radical prostatectomy (RP) is one of the leading primary treatment options for patients with prostate cancer (PCa) [1–3]. Depending on risk factors, up to 50% / 65% of the patients develop biochemical recurrence within five / ten years after RP, respectively [4,5]. For these patients, who are prone to systemic progression [6,7], salvage radiotherapy (SRT) with or without additional androgen deprivation therapy (ADT) provides a second chance of cure with around 97% overall survival at 5 years and still 88% at 10 years after SRT [8,9].